In a patient with recent psychotic hospitalization who independently discontinued olanzapine (Zyprexa) and buspirone, and is now stable on bupropion and trazodone without active psychotic, depressive, or manic symptoms, what antipsychotic and mood‑stabilizing medication regimen should be initiated to prevent relapse while minimizing adverse effects?

Reinitiate Olanzapine at Low Dose for Relapse Prevention

Given this patient's recent psychotic episode requiring hospitalization and her self-discontinuation of olanzapine just two weeks ago, you should reinitiate olanzapine at a low dose (2.5–5 mg daily) to prevent relapse, as continuing antipsychotic treatment after symptom remission significantly reduces relapse risk in psychotic disorders. 1

Rationale for Antipsychotic Continuation

The APA guidelines explicitly recommend that patients with schizophrenia or psychotic disorders whose symptoms have improved with an antipsychotic medication continue treatment with that same medication 1. This patient achieved remission on olanzapine, making it the evidence-based choice for maintenance therapy.

Critical relapse prevention data: In patients with psychotic depression who achieved remission on sertraline plus olanzapine, continuing the antipsychotic reduced relapse risk dramatically—only 20.3% relapsed on continued olanzapine versus 54.8% on placebo over 36 weeks (hazard ratio 0.25) 2. While this patient's presentation differs (brief psychotic episode vs. psychotic depression), the principle of antipsychotic continuation after acute response applies across psychotic spectrum disorders.

Specific Medication Regimen

Antipsychotic:

• Restart olanzapine 2.5–5 mg once daily 3
• This lower starting dose addresses her concerns about cognitive clouding and sedation
• The FDA label specifies 5 mg as the recommended starting dose for patients who may be more pharmacodynamically sensitive 3
• Target dose: 5–10 mg daily based on tolerability and symptom monitoring
• Do NOT exceed 20 mg daily 3

Current medications to continue:

• Bupropion: Continue current dose—it has not caused psychotic worsening in this patient and may help with energy/motivation 4, 5
• Trazodone: Continue for sleep maintenance

Do NOT restart buspirone: Buspirone has documented cases of worsening psychosis in patients with psychotic spectrum disorders 6 and offers no relapse prevention benefit for her primary condition.

Mood Stabilizer Consideration

A mood stabilizer is NOT indicated at this time based on the clinical presentation:

• Her "high energy" and productivity represent her longstanding baseline personality traits, not episodic mania
• Both patient and collateral source confirm these are chronic characteristics, not a change from baseline
• No current evidence of decreased need for sleep (she's sleeping 7–8 hours), excessive spending beyond baseline, or goal-directed activity exceeding her usual functioning
• The recent impulsive shopping occurred during the acute psychotic episode and has resolved

Monitor closely for: Any true episodic change suggesting bipolar disorder (distinct periods of decreased sleep need, marked increase in spending, uncharacteristic risk-taking). If these emerge, consider adding lithium or valproate.

Addressing Metabolic and Cognitive Concerns

Her subjective improvement after stopping olanzapine reflects real adverse effects:

Weight and metabolic monitoring:

• Olanzapine causes significant weight gain (0.13 lb/day in maintenance studies), increased waist circumference, and elevated cholesterol 2
• Concurrent metformin 500–850 mg daily is recommended to attenuate olanzapine-associated weight gain 7
• Monitor weight, waist circumference, lipids, and glucose monthly

Cognitive effects:

• Lower doses (2.5–5 mg) typically produce less sedation than the doses she likely received during hospitalization
• Dosing at bedtime minimizes daytime cognitive impairment
• If sedation persists, consider switching to risperidone or aripiprazole after 4 weeks 7

Critical Monitoring Plan

Weekly for first month:

• Psychotic symptoms (hallucinations, paranoia, delusions)
• Mood stability and sleep patterns
• Medication adherence
• Weight and metabolic parameters

Red flags requiring immediate intervention:

• Re-emergence of auditory hallucinations or paranoid ideation
• True manic symptoms (decreased sleep need, excessive spending, marked agitation)
• Suicidal ideation
• Medication non-adherence

Common Pitfalls to Avoid

1. Do not leave her without antipsychotic coverage: The two-week gap since discontinuation already places her at elevated relapse risk. The INTEGRATE guidelines emphasize early, proactive treatment to prevent relapse 7.

2. Do not dismiss her cognitive complaints: These are valid concerns. Address them through dose optimization and metabolic co-treatment rather than abandoning antipsychotic therapy entirely.

3. Do not misdiagnose her baseline personality as hypomania: High-functioning, energetic individuals with Type A personalities can be misidentified as having bipolar disorder. The key distinction is episodic change versus stable trait.

4. Do not restart buspirone: It provides no benefit for psychosis prevention and carries risk of symptom exacerbation in psychotic spectrum disorders 6.

Alternative if Olanzapine Intolerable

If she refuses olanzapine or develops intolerable side effects despite low-dose strategy:

Second-line options:

• Risperidone 1–2 mg daily (less metabolic burden than olanzapine) 7
• Aripiprazole 5–10 mg daily (partial D2 agonist with favorable metabolic profile) 7

Both require 4 weeks at therapeutic dose before assessing efficacy 7. Cross-titration should be gradual when switching antipsychotics.

The priority is relapse prevention through continued antipsychotic treatment, balanced against tolerability through low-dose initiation, metabolic co-treatment, and close monitoring.